Drug General Information
Drug ID
D0V9WF
Former ID
DAP001395
Drug Name
Lestaurtinib
Synonyms
A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
Drug Type
Small molecular drug
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Approved (orphan drug) [537117], [541016]
Myeloid leukemia [ICD9: 208.9; ICD10:C92] Phase 3 [537117], [541016]
Psoriasis [ICD9: 696; ICD10:L40] Phase 2/3 [528330], [529136], [541016]
Acute myeloid leukemia; Prostate cancer; Pancreatic cancer [ICD9: 140-199, 140-229, 157, 205.0, 210-229; ICD10:C25, C92.0, D10-D36, D3A] Phase 2 [537117], [541016]
Therapeutic Class
Anticancer Agents
Company
Cephalon; Kyowa Hakko Kogyo
Structure
Download
2D MOL

3D MOL

Formula
C26H21N3O4
InChI
InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
InChIKey
UIARLYUEJFELEN-LROUJFHJSA-N
CAS Number
CAS 111358-88-4
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) FL cytokine receptor Target Info Modulator [528330], [529136]
KEGG Pathway Cytokine-cytokine receptor interaction
Hematopoietic cell lineage
Pathways in cancer
Transcriptional misregulation in cancer
Acute myeloid leukemia
Central carbon metabolism in cancer
References
Ref 528330A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006 Nov 15;108(10):3262-70. Epub 2006 Jul 20.
Ref 529136Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008 Jun 15;111(12):5663-71. Epub 2007 Nov 5.
Ref 537117Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
Ref 541016(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
Ref 528330A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006 Nov 15;108(10):3262-70. Epub 2006 Jul 20.
Ref 529136Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008 Jun 15;111(12):5663-71. Epub 2007 Nov 5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.